Trade Report: Today, Syros Pharmaceuticals Inc. (SYRS) Research Coverage Started at Oppenheimer Holdings Inc.

Today, Syros Pharmaceuticals Inc. (SYRS) Research Coverage Started at Oppenheimer Holdings Inc.

Equities research analysts at Oppenheimer Holdings Inc. assumed coverage on shares of Syros Pharmaceuticals Inc. (NASDAQ:SYRS) in a research note issued on Tuesday. The firm set an “outperform” rating on the stock.

Other equities analysts have also issued reports about the stock. Piper Jaffray Cos. set a $20.00 price objective on shares of Syros Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, November 14th. Zacks Investment Research upgraded shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, October 20th. HC Wainwright restated a “hold” rating and issued a $10.00 price objective on shares of Syros Pharmaceuticals in a research report on Friday, September 9th. Wedbush restated an “outperform” rating and issued a $18.00 price objective on shares of Syros Pharmaceuticals in a research report on Monday, November 14th. Finally, Cann initiated coverage on shares of Syros Pharmaceuticals in a research report on Monday. They issued an “outperform” rating and a $28.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $19.60.

Syros Pharmaceuticals (NASDAQ:SYRS) traded up 5.33% during trading on Tuesday, reaching $14.04. 1,954 shares of the company’s stock traded hands. Syros Pharmaceuticals has a 12 month low of $8.16 and a 12 month high of $21.50. The firm has a 50 day moving average price of $13.48 and a 200-day moving average price of $13.08. The firm’s market cap is $328.26 million.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings data on Monday, November 14th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by $0.11. On average, analysts forecast that Syros Pharmaceuticals will post ($4.03) earnings per share for the current fiscal year.

A number of large investors have recently made changes to their positions in the stock. California State Teachers Retirement System bought a new stake in shares of Syros Pharmaceuticals during the third quarter valued at about $137,000. Spark Investment Management LLC acquired a new stake in shares of Syros Pharmaceuticals during the third quarter worth $160,000. Hamilton Lane Advisors LLC acquired a new stake in shares of Syros Pharmaceuticals during the third quarter worth $193,000. Morgan Stanley acquired a new stake in shares of Syros Pharmaceuticals during the third quarter worth $469,000. Finally, AWM Investment Company Inc. acquired a new stake in shares of Syros Pharmaceuticals during the third quarter worth $660,000. Institutional investors and hedge funds own 54.56% of the company’s stock.

About Syros Pharmaceuticals

Related posts

Leave a Comment